左西替利嗪、孟鲁司特联合卡介菌素对慢性荨麻疹的治疗效果分析

摘要/Abstract

摘要： 目的研究左西替利嗪、孟鲁司特联合卡介菌素治疗慢性荨麻疹的效果。方法选取山东第一医科大学附属肥城医院2019年2月~2020年11月收治的慢性荨麻疹患者78例,按随机数表法分为对照组和观察组,每组39例。对照组采用卡介菌素联合孟鲁司特治疗,观察组采用左西替利嗪、孟鲁司特联合卡介菌素治疗。比较两组患者生活质量评分、治疗效果、临床症状消退时间。结果治疗后,观察组患者临床症状消退时间显著短于对照组,差异有统计学意义（P<0.05）。治疗后,观察组患者治疗效果显著高于对照组,差异有统计学意义（P<0.05）。治疗后,观察组患者生活质量评分显著高于对照组,差异有统计学意义（P<0.05）。结论左西替利嗪、孟鲁司特联合卡介菌素治疗慢性荨麻疹,能够缩短患者临床症状消退时间,提升患者治疗效果,同时提升患者生活质量,能够给临床治疗慢性荨麻疹方面提供更多的参照,并可在临床应用。

关键词: 左西替利嗪, 治疗, 孟鲁司特, 卡介菌素, 慢性荨麻疹

Abstract: Objective To study the the therapeutic effect of levocetirizine, montelukast combined with BCG Bacillus Calmette-Guerin on chronic urticaria patients. Methods A total of 78 patients with chronic urticaria admitted to Feicheng Hospital Affiliated to Shandong First Medical University from February 2019 to November 2020 were selected. They were included and randomly divided into the observation group and the control group. Among them, 39 patients in the observation group received the therapy proctocol of levocetirizine, montelukast combined with BCG, while 39 patients in the control group received Bacillus Calmette-Guerin combined with montelukast. Quality of life score, treatment efficacy and clinical symptom subsidence time were administated between two groups. Results After treatment, the clinical symptom subsidence time in the observation group was significantly shorter than that in the control group (P<0.05). After treatment, the total efficiency of the observation group was significantly higher than that of the control group (P<0.05). After treatment, the quality of life score of the observation group was significantly higher than that of the control group (P<0.05). Conclusion The therapy protocol of levocetirizine, montelukast combined with BCG in chronic urticaria could significatly improve the clinical symptom subsidence time, improve the therapeutic effect and increase the quality of life score.

Key words: levocetirizine, montelukast, Bacillus Calmette-Guerin, chronic urticaria

中图分类号:

R758.24

刘国芳, 张志杰. 左西替利嗪、孟鲁司特联合卡介菌素对慢性荨麻疹的治疗效果分析[J]. 中华养生保健, 2022, 40(8): 4-6.

LIU Guo-fang, ZHANG Zhi-jie. Analysis of the Therapeutic Effect of Levocetirizine, Montelukast combined with BCG on Chronic Urticaria[J]. ZHONGHUA YANGSHENG BAOJIAN, 2022, 40(8): 4-6.

参考文献

[1] 胡惠清,李静,方坤,等.加味荆防方联合盐酸西替利嗪片治疗风热型慢性荨麻疹的临床观察[J].中国皮肤性病学杂志,2019,33(9):1101-1106.
[2] 徐延峰,杜威萍,骆志成,等.枸地氯雷他定治疗慢性荨麻疹的疗效及对血清白细胞介素23和33、趋化因子PARC/CCL-18的影响[J].中华皮肤科杂志,2019,52(5):337-339.
[3] 郎小青,续凤凤,郭书萍.枸地氯雷他定联合维生素D滴剂治疗慢性自发性荨麻疹的疗效观察[J].武警医学,2020,31(7):561-564.
[4] 吴菲,刘丽锋,杨莉佳.地氯雷他定对慢性荨麻疹患者的疗效及预后的影响分析[J].国际医药卫生导报,2019,25(14):2348-2350.
[5] 孙田,王珺,王东.当归四逆加吴萸生姜汤加味联合枸地氯雷他定片治疗慢性荨麻疹的临床观察[J].世界中医药,2020,15(2):256-260.
[6] 中华医学会皮肤性病学分会.荨麻疹诊疗指南(2007版)[J].中华皮肤科杂志,2007,40(10):591-593.
[7] 王月萍,陈维宁,马骏,等.探讨玉屏风颗粒联合枸地氯雷他定片治疗慢性荨麻疹的临床效果及作用研究[J].世界复合医学,2019, 5(9): 120-122,138.
[8] 朴莉玲,张春韶,唐妮,等.探讨复方甘草酸苷片联合枸地氯雷他定片治疗慢性特发性荨麻疹的临床疗效[J].中国实用医药,2019, 14(24):77-79.
[9] 余鑫海,高贵云.左西替利嗪、孟鲁司特联合卡介菌素对慢性荨麻疹的治疗效果观察[J].中国社区医师,2019,35(34):81-82.
[10] 段志国,王希瑞.多皮饮联合玉屏风散加减治疗慢性荨麻疹的有效性与安全性[J].临床医学研究与实践,2021,6(7):116-117,126.
[11] 孙蔚凌,吴国勤,王军.富马酸依美斯汀治疗慢性荨麻疹的疗效研究[J].重庆医学,2021,50(4):650-653.
[12] 王薇,伍振飞,欧伟洪.依巴斯汀联合金水宝胶囊递减疗法治疗慢性荨麻疹的临床观察[J].中国中西医结合杂志,2021,41(7):881-882.
[13] 王栩芮,傅文斌,孙弋淇,等.当归饮子联合西替利嗪治疗慢性荨麻疹患者的疗效及对免疫炎症因子的影响[J].中国中西医结合杂志,2021,41(7):877-880.
[14] 林永丽,孙亚飞,杨灿.依巴斯汀、脾氨肽联合自血穴位注射治疗ASST(+)慢性荨麻疹疗效及对患者免疫炎性因子的影响[J].陕西中医,2019,40(4):502-504.
[15] 石岩硕,王祁民,邱学佳,等.雷公藤多苷片联合地氯雷他定治疗慢性荨麻疹疗效和安全性的Meta分析[J].中国中药杂志,2019, 44(16): 3551-3557.